Erasca, Inc.
ERAS
Updated: 22/09/2026, 09:06:46
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
No summaries found.
- Share price
- $15.04
- Market cap
- $5.22B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Jonathan E. Lim
- Employees
- 103
- IPO date
- 16/07/2021
- Beta
- 0.645
- Last dividend
- $0.00
- Day range
- $14.95 – $15.29
- 52-week range
- $1.75 – $24.28
- 1-day performance
- 1.83%
- 1-year performance
- 759.43%
- Current drawdown (1Y)
- -38.06%
- CIK
- 0001761918
- CUSIP
- 29479A108
- ISIN
- US29479A1088
- Created
- 07/12/2025, 03:49:02
- Last update
- 22/09/2026, 09:06:46
Track Erasca, Inc. with an AI analyst
See which prediction-market events move ERAS, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Newsfile Corp • STOCK • 14/06/2026, 14:00:00
ERAS EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
Newsfile Corp • STOCK • 13/06/2026, 09:22:00
Securities Fraud Investigation Into Erasca, Inc. (ERAS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Business Wire • STOCK • 12/06/2026, 17:00:00
Erasca, Inc. (ERAS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Business Wire • STOCK • 12/06/2026, 15:42:00
Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
GlobeNewsWire • STOCK • 12/06/2026, 14:21:00
ERAS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
GlobeNewsWire • STOCK • 12/06/2026, 11:44:00
Berger Montague PC Investigating Claims on Behalf of Erasca, Inc. (ERAS) Investors After Class Action Filing
Newsfile Corp • STOCK • 12/06/2026, 11:41:00
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with the Schall Law Firm
GuruFocus • STOCK • 12/06/2026, 00:00:00
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Business Wire • STOCK • 11/06/2026, 23:36:00
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit
PRNewsWire • STOCK • 11/06/2026, 22:46:00
INVESTOR ALERT: Securities Class Action Filed Against Erasca, Inc. – Investors Encouraged to Contact Kirby McInerney LLP
Business Wire • STOCK • 11/06/2026, 22:00:00
Rosen Law Firm Urges Erasca, Inc. (NASDAQ: ERAS) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Business Wire • STOCK • 11/06/2026, 21:15:00